More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

therapy
US Companies Launch CRISPR Clinical Trial
US Companies Launch CRISPR Clinical Trial
Catherine Offord | Sep 3, 2018
The Germany-based study will test an ex vivo genome-editing therapy for the inherited blood disorder β-thalassemia.
Resurrecting Smells
Resurrecting Smells
The Scientist Staff | Oct 31, 2016
Visit the Monell Chemical Senses Center in Philadelphia, where researchers are striving to find a cure for anosmia, the loss of a sense of smell.
Cognitive Neuroscience Lurking in Art
Cognitive Neuroscience Lurking in Art
Kerry Grens | Oct 19, 2015
What can neuroscientists learn from the masters and other artists?